

Umit Tursen · Lulufer Tamer · Gulcin Eskandari  
Tamer Irfan Kaya · Nurcan Aras Ates · Guliz Ikizoglu  
Ugur Atik

## Glutathione S-transferase polymorphisms in patients with Behçet's disease

Received: 2 January 2004 / Revised: 1 June 2004 / Accepted: 8 July 2004 / Published online: 7 August 2004  
© Springer-Verlag 2004

**Keywords** Glutathione S-transferase · Polymorphisms · Behçet's disease

The glutathione S-transferases (GST) are a multigene family of enzymes involved in the detoxification and, in a few instances, activation of a wide variety of chemicals. GST might contribute to protection against oxidative stress, either by direct inactivation of peroxidized lipids and DNA or by detoxification of xenobiotics, which are known cofactors for radical formation. The GST isoenzymes expressed in human tissue comprise the alpha (A), mu (M), pi (P), theta (T), kappa (K), omega (O) and zeta (Z) gene families. Among these classes of GST, GSTM1, GSTM3, GSTT1, GSTP1, and GSTZ1 have been shown to be polymorphically distributed [1, 2].

Behçet's disease (BD) is a multisystemic disease of unknown etiology characterized by chronic relapsing oral–genital ulcers and uveitis. Multiple systemic associations including articular, gastrointestinal, cardiopulmonary, neurologic and vascular involvement are also observed [3, 4]. Although the etiopathogenesis of the disease remains unknown, increased neutrophil functions such as chemotaxis, phagocytosis and excessive production of reactive oxygen species (ROS), including superoxide anion, which may be responsible for oxidative tissue damage seen in BD, and also immunological alterations, and T lymphocyte abnormalities in both

subpopulation and function have been considered to be correlated with the etiopathogenesis of BD [5, 6].

Enrolled in the study were 56 subjects with BD (35 women and 21 men), and 178 healthy control subjects (96 women and 82 men). The mean ( $\pm$ SD) age of the patients was  $41.51 \pm 12.41$  years, and of the control subjects was  $49.69 \pm 14.01$  years. All BD patients fulfilled the International Study Group criteria for the diagnosis of BD [7]. Control subjects were selected from among healthy persons without a history of malignancy, atopy, or autoimmune diseases. The study was approved by the Ethics Committee of Mersin University.

Blood was collected in EDTA-containing tubes and DNA was extracted from the lymphocytes using a high pure template preparation kit (Roche Diagnostics, Mannheim, Germany). The polymorphisms *GSTT1*, *GSTM1* and *GSTP1* were determined by real-time PCR with a LightCycler instrument using hybridization probes in combination with a LightCycler DNA Master Hybridization Probes kit (Roche Diagnostics). The PCR primers and the hybridization probes were synthesized by Tib Molbiol (Berlin, Germany). The sequences and the hybridization probes are shown in Table 1. The PCR conditions, essentially those described by Ko et al. [8], were as follows: 4 mmol/l  $MgCl_2$ , 0.2  $\mu$ mol/l of each hybridization probe, 10 pmol of each PCR primer, 2  $\mu$ l of the LightCycler DNA Master Hybridization Mix and 50 ng of genomic DNA in a final volume of 20  $\mu$ l. These conditions were the same for the amplification of all three mutations.

The cycling program for *GSTT1* comprised 45 cycles of denaturation (95°C, 0 s, ramp rate 20°C/s), annealing (66°C, 10 s, ramp rate 20°C/s) and extension (72°C, 19 s, ramp rate 20°C/s). After amplification a melting curve was generated by holding the reaction at 45°C for 10 s and then heating slowly (ramp rate 0.1°C/s) to 95°C. The programs for *GSTM1* and *GSTP1* were identical and comprised 45 cycles of denaturation (95°C, 0 s, ramp rate 20°C/s), annealing (66°C, 10 s, ramp rate 20°C/s) and extension (72°C, 7 s, ramp rate 20°C/s). After amplification a melting curve was generated by

U. Tursen (✉) · T. I. Kaya · G. Ikizoglu  
Department of Dermatology, Faculty of Medicine,  
Mersin University, 33070 Zeytinlibahce-Mersin, Turkey  
E-mail: utursen@mersin.edu.tr  
Tel.: +90-324-3374300 ext. 1171  
Fax: +90-324-3374305

L. Tamer · G. Eskandari  
Department of Biochemistry, Faculty of Medicine,  
Mersin University, Mersin, Turkey

N. A. Ates · U. Atik  
Department of Medical Biology and Genetics,  
Faculty of Medicine, Mersin University,  
Mersin, Turkey

**Table 1** Polymerase chain reaction (PCR) primer sequences and hybridization probes for glutathione S-transferase (GST) M1, T1 and P1

Gene	PCR primers	Hybridization probes
GSTM1	5'-GAACTCCCTGAAAAGCTAAAGC-3' 5'-GTTGGGCTCAAATATACGGTGG-3'	5'-LCR640-ATGGCCGCTTCCCAGAAACTCTG-3' 5'-TCACTCCTCCTTTACCTTGTTTCCTGCAAA-FL-3'
GSTT1	5'-TTCCTTACTGGTCCCTCACATCTC-3' 5'-TCCAGGTCAACCGGATCAT-3'	5'-LCR640-TCDAAGGCCGACCCAAAGCTGGC-3' 5'-CCGTGGGTGCTGGCTGCCAAGT-FL-3'
GSTP1	5'-ACCCAGGGCTCTATGGGAA-3' 5'-TGAGGGCACAAGAAGCCCCT-3'	5'LCR640-TGTGAGCATCTGCACCAAGGGTTGGGG-3' 5'-TGCAAATACATCTCCCTCATCTACACAAC-FL-3'
$\beta$ -Globin	5'-CAACTTCATCCACGTTACCC-3' 5'-GAAGAGCCAAGGACAGGTAC-3'	

holding the reaction at 45°C for 15 s and than heating slowly (ramp rate 0.1°C/s) to 95°C. The fluorescence signal was plotted against temperature to give melting curves for each sample. Peaks were obtained at 59°C for the B allele and at 63°C for the A allele for GSTP1 genotype. The quantification program of LightCycler instrument evaluated the presence of either of GSTT1 and GSTM1.

Student's *t*-test was used to compare the ages of the two groups. The chi-squared test was used to compare two independent proportions. All values are presented as mean and standard deviation (SD). *P* values < 0.05 were considered statistically significant. The association between *GSTM1*, *GSTT1* and *GSTP1* polymorphisms, and BD was modeled through multivariate logistic regression analysis. The GST assays place individuals into distinct categories: those with present or null genotypes for *GSTM1* and *GSTT1*, and homozygous 105 Ile or heterozygous or homozygous 105 Val genotypes for *GSTP1*. Odds ratio and confidence intervals were used to analyze the frequency of occurrence of *GSTM1*, *GSTT1* and *GSTP1* genotypes in patients with BD compared to the control group. The reference group consisted of individuals with three putative low-risk genotypes, i.e. the presence of *GSTM1* (non-deleted), *GSTT1* (non-deleted), and *GSTP1* (homozygous Ile 104) functional alleles.

Patients with BD showed a higher prevalence of the GSTM1-null genotype than the healthy individuals (41.1% and 24.2%, respectively; OR 2.01, 95% CI 1.15–3.84). But the GSTT1(null) and GSTP1(val/val) gene polymorphisms were not associated with an increased risk of developing BD (OR 0.79, 95% CI 0.36–1.69; OR 0.49, 95% CI 0.10–2.31, respectively; Table 2). We analyzed the genotypes of GSTM1 and GSTT1 in combination to evaluate whether the combination of these genotypes is associated with the development of BD. No relationship was observed between the null combination of the GSTM1 and GSTT1 genotype polymorphisms and risk of BD (OR 1.85; 95% CI 0.52–6.59; Table 3).

In spite of an unknown etiology, it is now accepted that reactive oxygen species produced by neutrophils may be related to the pathogenesis of BD. Increased malondialdehyde and superoxide dismutase levels, but decreased glutathione peroxidase activities in erythrocytes have been observed in patients with BD [9, 10].

**Table 2** GST genotypes and the risk of developing Behçet's disease

Variable	Cases ( <i>n</i> = 56)	Controls ( <i>n</i> = 178)	
	<i>n</i> (%)	<i>n</i> (%)	OR (95% CI)
<i>GSTM1</i> <sup>a</sup>			
Present	33 (58.9)	135 (75.8)	1 (referent)
Null	23 (41.1)	43 (24.2)	2.01 (1.15–3.84)
<i>GSTT1</i> <sup>a</sup>			
Present	45 (80.4)	132 (74.2)	1 (referent)
Null	11 (19.6)	46 (25.8)	0.79 (0.36–1.69)
<i>GSTP1</i>			
Ile/Ile	32 (57.1)	86 (48.3)	1 (referent)
Ile/Val	22 (39.3)	78 (43.8)	0.85 (0.45–1.62)
Val/Val	2 (3.6)	14 (7.9)	0.49 (0.10–2.31)

<sup>a</sup>Carriers of at least one intact allele are used as reference

Toxic compounds such as pesticides and insecticides have been incriminated in BD. Recently, Aynacioglu et al. have shown that the N-acetyltransferase 2\*5B allele is slightly higher in patients with BD. This enzyme contributes to the metabolism of drugs and toxic compounds [11].

GST are a family of proteins that conjugate glutathione to various electrophilic substances and thus are thought to play an important role in the prevention of toxic injuries in various tissues. GST are present in the cytosol of most organs, whose expression is tissue specific. Liver, kidney, and muscle contain multiple forms of both the alpha and mu class of GST. The pi form isozyme is the predominant form in the placenta and is also found in the skin and in human keratinocytes [12]. In inflammatory diseases, the main source of ROS is inflammatory cellular infiltrate. Stimulated monocytes produce superoxide, the respiratory burst of infiltrating polymorphonuclear neutrophils in inflamed skin produces high local levels of superoxide anion and hydrogen peroxide. Production of nitric oxide by nitric oxide synthase also occurs in keratinocytes. Excessive pro-

**Table 3** Distribution of GSTT1 and GSTM1 genotypes in combination

	Both null genotypes, <i>n</i> (%)	Others, <i>n</i> (%)
Patients ( <i>n</i> = 56)	4 (7.1)	52 (92.9)
Control ( <i>n</i> = 176)	7 (4.0)	169 (96.0)
OR (95% CI)	1.85 (0.52–6.59)	

duction of ROS results in peroxidation of cell membrane lipids and damage to proteins and DNA. The skin possesses considerable endogenous protection against oxidative damage, as it is equipped with several antioxidants. Reduced glutathione has gained attention as the central cellular antioxidant in the skin that also participates in the metabolism of xenobiotics and leukotriene synthesis [13].

In our study, patients with BD showed a higher prevalence of the GSTM1 null genotype than healthy individuals. Hereditary deficiencies of this enzyme activity may lead to an imbalance between pro- and antioxidant systems resulting in excessive ROS formation. ROS are important mediators of inflammatory and immune reactions *in vivo*, leading to oxidative cellular damage [14]. As shown in patients with BD, excessive ROS production by activated neutrophils and the presence of an impaired oxidant/antioxidant balance in both neutrophils and plasma may lead to oxidative damage by ROS, as reflected by decreased GST enzyme activity. Further studies on larger groups are needed to determine the prevalence of GST polymorphisms in patients with BD and to determine whether they constitute a major risk factor in the development of BD.

---

## References

1. Sheehan D, Meade G, Foley VM, Dowd CA (2001) Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochem J* 360:1–16
2. Eaton DL, Bammler TK (1999) Concise review of the glutathione S-transferases and their significance to toxicology. *Toxicol Sci* 49:156–164
3. Behçet H (1937) Über rezidivierende Aphthosen durch ein virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. *Dermatol Monatsschr Wochenschr* 105:1152–1157
4. Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behçet's disease; an analysis of 2147 patients. *Yonsei Med J* 38:423–427
5. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M (1982) Auto-oxidative damage in Behçet's disease—endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. *Clin Exp Immunol* 49:247–255
6. O'Duffy JD (1994) Behçet's disease. *Curr Opin Rheumatol* 6:39–43
7. International Study Group for Behçet's Disease Contributors (1991) Evaluation of diagnostic ("classification") criteria in Behçet's disease: toward internationally agreed criteria. In: O'Duffy, Kökmen E (eds) Behçet's disease basic and clinical aspects. Marcel Dekker, New York, pp 11–39
8. Ko Y, Koch B, Harth V, et al (2000) Rapid analysis of GSTM1, GSTT1 and GSTP1 polymorphisms using real-time polymerase chain reaction. *Pharmacogenetics* 10:1–4
9. Kose K, Yazici C, Cambay N, Ascioğlu O, Dogan P (2002) Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behçet's disease. *Tohoku J Exp Med* 197:9–16
10. Taysi S, Kocer I, Memisogullari R, Kiziltunc A (2002) Serum oxidant/antioxidant status in patients with Behçet's disease. *Ann Clin Lab Sci* 32:377–382
11. Aynacioglu AS, Bozkurt A, Nacak M, Kortunay S, Tunc R, Dincel A, Kayaalp SO (2001) N-acetyltransferase polymorphism in patients with Behçet's disease. *Eur J Clin Pharmacol* 57:659–662
12. Seo KI, Cho KH, Park KC, Youn JI, Eun HC, Kim KT, Park SC (1996) Change of glutathione S-transferases in the skin by ultraviolet B radiation. *J Dermatol Sci* 13:153–160
13. Kaur S, Zilmer M, Eisen M, Kullisaar T, Rehema A, Vihalemm T (2001) Patients with allergic and irritant contact dermatitis are characterized by striking change of iron and oxidized glutathione status in nonlesional skin area of the skin. *J Invest Dermatol* 116:886–890
14. Freitas JP, Filipe P, Yousefi A, et al (1998) Oxidative stress in Adamantiades-Behçet's disease. *Dermatology* 197:343–348